Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Recipient : Nona Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement
Details : By harnessing the immense expertise and resources of both companies, the collaboration aims to accelerate the development of innovative therapeutics for immunological disorders with highly unmet needs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 13, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Recipient : Nona Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : IGT-427
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Mosaic Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IGT-427 is a bispecific antibody that potently blocks VEGF and activates Tie-2. Variants of IGT-427 had long intravitreal half-lives, suggesting potential for a less frequently administered and highly efficacious treatment for diabetic macular edema and ...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 05, 2022
Lead Product(s) : IGT-427
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Mosaic Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable